Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Ma, Zhen Bin ^a   Li, Kun ^a   Wang, Jian ^a   Guo, Guang Hong ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Allele; Colorectal cancer; KAI1 CD82; Polymorphism

Indexed keywords

CD82 ANTIGEN; CD82 PROTEIN, HUMAN;

ALLELISM; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; COLON CANCER; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; ADULT; AGED; ALLELE; ASIAN; CASE CONTROL STUDY; CELL DIFFERENTIATION; COLON TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; RISK; ASIAN CONTINENTAL ANCESTRY GROUP;

ADULT; AGED; ALLELES; ANTIGENS, CD82; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; COLONIC NEOPLASMS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 84880182381     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0668-7     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi:10.3322/caac.20107.
2. Zhu QC, Jin ZM. Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2011;33(5):388-90.
3. Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249(1):87-96. doi:10.1016/j.canlet.2006.12. 021.
4. Moreaux J, Catala M. Carcinoma of the colon: long-term survival and prognosis after surgical treatment in a series of 798 patients. World J Surg. 1987;11(6):804-9.
5. Burt RW. Strategies for colon cancer screening with considerations of cost and access to care. J Natl Compr Canc Netw. 2010;8(1):2-5.
6. Ye Y, Madison B, Wu X, Rustgi AK. A LIN28B polymorphism predicts for colon cancer survival. Cancer Biol Ther. 2012;13(14): 1390-5. doi:10.4161/cbt.22336.
7. Zhang L, Zhang G, Wang P, Gong J, Cao Y, Tang L. Association of vascular endothelial growth factor -2578C/A gene polymorphism in Chinese patients with colon cancer. Genet Test Mol Biomarkers. 2011;15(3):117-21. doi:10.1089/gtmb. 2010.0166.
8. Slattery ML, Herrick J, Curtin K, Samowitz W, Wolff RK, Caan BJ, et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res. 2010;70(4):1479-85. doi:10.1158/0008-5472.CAN-08-1792.
9. Rubinstein E, Le Naour F, Billard M, Prenant M, Boucheix C. CD9 antigen is an accessory subunit of the VLA integrin complexes. Eur J Immunol. 1994;24(12):3005-13. doi:10.1002/eji. 1830241213.
10. Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME. Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). J Immunol. 1996;157(5):2039-47.
11. Hemler ME, Mannion BA, Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta. 1996;1287(2-3):67-71.
12. Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol Today. 1994;15(12):588-94. doi:10.1016/0167-5699(94)90222- 4.
13. Hashida H, Takabayashi A, Tokuhara T, Hattori N, Taki T, Hasegawa H, et al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer. 2003;89(1):158-67. doi:10.1038/sj.bjc.6601015.
14. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 1996;56(19): 4387-90.
15. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995; 268(5212):884-6.
16. Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M, et al. Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer. 1998;79(4):349-55. doi:10.1002/(SICI)1097- 0215(19980821)79: 4\349:AID-IJC7[3.0.CO;2-V.
17. Yu Y, Yang JL, Markovic B, Jackson P, Yardley G, Barrett J, et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res. 1997;3(7):1045-9.
18. Yang X, Welch DR, Phillips KK, Weissman BE, Wei LL. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett. 1997;119(2):149-55. doi:S0304-3835(97)00273-5.
19. Higashiyama M, Kodama K, Yokouchi H, Takami K, Adachi M, Taki T, et al. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis. Cancer. 1998;83(3):466-74. doi:10.1002/(SICI) 1097-0142(19980801)83:3<466:AID-CNCR15>3.0.CO;2-U.
20. Hinoda Y, Adachi Y, Takaoka A, Mitsuuchi H, Satoh Y, Itoh F, et al. Decreased expression of the metastasis suppressor gene KAI1 in gastric cancer. Cancer Lett. 1998;129(2):229-34. doi:S0304-3835(98)00112-8.
21. Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 1999;79(7-8): 1168-73. doi:10.1038/sj.bjc.6690186.
22. Dong JT, Isaacs WB, Barrett JC, Isaacs JT. Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics. 1997;41(1):25-32. doi:10.1006/geno.1997.4618.
23. Nazir M, Kayani MR, Malik FA, Masood N, Kayani MA. Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin. Asian Pac J Cancer Prev. 2011;12(10):2767-71.
24. Boland CR. Molecular genetics of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci. 2000;910:50-9; discussion 9-61.
25. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
26. Miyake M, Hakomori SI. A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry. 1991;30(13):3328-34.
27. Hashida H, Takabayashi A, Adachi M, Imai T, Kondo K, Kohno N, et al. The novel monoclonal antibody MH8-4 inhibiting cell motility recognizes integrin alpha 3: inverse of its expression withmetastases in colon cancer. Int J Oncol. 2001;18(1):89-95.
28. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. 2002;122(2):376-86. doi:S0016508502084482.
29. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146(2): 389-403.
30. Kolesnikova TV, Stipp CS, Rao RM, Lane WS, Luscinskas FW, Hemler ME. EWI-2 modulates lymphocyte integrin alpha4beta1 functions. Blood. 2004;103(8):3013-9. doi:10.1182/blood-2003-07-2201.
31. Miyazaki T, Kato H, Shitara Y, Yoshikawa M, Tajima K, Masuda N, et al. Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer. 2000;89(5):955-62. doi:10.1002/1097- 0142(20000901)89: 5<955:AID-CNCR3>3.0.CO;2-Z.
32. Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, et al. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate. 1997;32(3):205-13. doi:10.1002/(SICI)1097-0045(19970801)32:3<205:AID-PROS7>3.0.CO;2-J.
33. Uzawa K, Ono K, Suzuki H, Tanaka C, Yakushiji T, Yamamoto N, et al. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin Cancer Res. 2002;8(3):828-35.